1. Academic Validation
  2. Protective effects of artesunate on the neurovascular unit by regulating PDGFRβ signaling in experimental cerebral malaria

Protective effects of artesunate on the neurovascular unit by regulating PDGFRβ signaling in experimental cerebral malaria

  • Biochem Pharmacol. 2025 Sep:239:117023. doi: 10.1016/j.bcp.2025.117023.
Yue Dai 1 Zhongyuan Zheng 1 Jiahui Ma 1 Chengcheng Liu 1 Shuoqiu Deng 1 Yan Liang 1 Tuo Liu 1 Luqi Wang 2 Yujie Li 3 Lina Chen 4
Affiliations

Affiliations

  • 1 Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China; Artemisinin Research Center, China Academy of Chinese Medical Sciences, Beijing 100700, China.
  • 2 Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China.
  • 3 Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China. Electronic address: yjli@icmm.ac.cn.
  • 4 Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China; Artemisinin Research Center, China Academy of Chinese Medical Sciences, Beijing 100700, China. Electronic address: lnchen@icmm.ac.cn.
Abstract

Cerebral malaria (CM) is a severe manifestation of malaria that significantly impacts the central nervous system, and current therapeutic options are inadequate in addressing the associated neurovascular damage. This study aimed to investigate the protective effects of artesunate on the neurovascular unit (NVU) in experimental cerebral malaria (ECM) by elucidating the underlying molecular mechanisms and signaling pathways involved. It demonstrated artesunate significantly reduced parasitemia and improved behavioral and physiological manifestations, and protected the NVU by increasing NeuN-positive neurons and αII-Spectrin and Connexin 43 (CX43) mRNA levels, while decreasing vascular endothelial growth factor α (VEGFα) mRNA and S100β levels. It also reduced astrocyte and microglia activation, mitigating neuroinflammation. Furthermore, our study indicates that platelet-derived growth factor receptor β (PDGFRβ) is crucial in the NVU protection conferred by artesunate. By using a PDGFRβ pharmacological inhibitor, NVU protective effects of artesunate during the severe episode of ECM were weakened, as evaluated by reduced NeuN-positive neurons and lower levels of Claudin5, zonula occludens-1 (ZO-1), CX43, and Synaptophysin. In addition, artesunate enhanced PDGFRβ protein and suppressed phosphatidylinositol 3-kinase (PI3K)/threonine kinase (Akt) pathway, which was elevated in ECM. The addition of a PDGFRβ Inhibitor increased PI3K/Akt signaling, suggesting the potential mechanism of artesunate to exert its protective effects on the NVU through the PDGFRβ and PI3K/Akt pathway in ECM. These results suggest that artesunate not only acts as an antimalarial agent but also have therapeutic potential in protecting the NVU through host proteins in cerebral malaria. This study lays groundwork for future research exploring new therapeutic strategies for malaria based on host proteins and signaling pathways.

Keywords

Artesunate; Experimental cerebral malaria; Neurovascular unit; PDGFRβ.

Figures
Products